Osteoporosis | Disease Landscape and Forecast | G7 | 2017

Publish date: November 2017

Login to access report

Patients with osteoporosis and osteopenia are at increased risk of suffering fractures. These fractures place a considerable burden on public health systems, and significant unmet need remains in the osteoporosis market for therapies that are safer and more efficacious, particularly in reducing the risk of nonvertebral fractures (e.g., hip fractures). The launch of several key new therapies, coupled with changes in treatment guidelines and in physician prescribing behavior, will lead to significant market changes over the 2014-2024 forecast period. The osteoporosis and osteopenia market is maturing, but launches of novel agents including Amgen/UCB’s romosozumab, and Radius’s abaloparatide, with both SC and TD routes of administration, will help to energize these markets.

Questions Answered:

  •  Several novel agents—Radius’s abaloparatide SC and TD, and Amgen/UCB’s romosozumab—are in late-stage development for the treatment of osteoporosis. Interviewed thought leaders express excitement about these novel therapies. What do interviewed thought leaders say about the pros and cons of each therapy? How do they anticipate using them as part of their osteoporosis treatment algorithm? Which agents in the current market are most vulnerable to being replaced by these novel therapies, and which ones will constrain uptake of the new drugs?
  •  A number of osteoporosis agents have recently lost or will lose patent protection during the forecast period, including raloxifene, risedronate, and teriparatide. Will these emerging generics act as a barrier to the uptake of novel agents? Which emerging agents offer improved efficacy, strong safety profiles, or more convenient administration and are capable of displacing generic formulations of these more established agents?
  • Chronic treatment with members of the bisphosphonate drug class (alendronate, risedronate, ibandronate, and zoledronate) is increasingly associated with adverse effects, including osteonecrosis of the jaw and an elevated risk for atypical subtrochanteric fractures. The bisphosphonates are the dominant drug class for the treatment of osteopenia and osteoporosis. How much impact will this association have on osteoporosis and osteopenia drug-treatment rates? To what extent will this association adversely affect sales of the bisphosphonates?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 20 country-specific interviews with experts.

Epidemiology: Osteopenia, osteoporosis, and total prevalent cases of FRAX high-risk.

Population segments in market forecast: osteopenia and osteoporosis.

Emerging therapies: Phase II: 5 drugs; Phase III: 3 drugs; preregistration: 2 drugs; registered: 0 drugs. Coverage of select preclinical and Phase I products.